Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
61 Cards in this Set
- Front
- Back
Micro 22
|
H Pylori
|
|
morphology of H pylori
|
gram negative, helical shaped microbe
|
|
how is H pylori encountered
|
acquired through fecal-oral or oral-oral routes
|
|
primary survival mechanism of H pylori in acidic stomach
|
urease production
|
|
toxin associated ith H pylori that supresses T cell responses
|
VacA
|
|
can cause cell death of gastric epithelium
|
VacA
|
|
can disrupt tight junctions between cells
|
CagA
|
|
most colonized pt present this way
|
asymptomatic chronic gastritis and low level inflammation
|
|
10% of H pylori develop this
|
duodenal ulcers
|
|
risk factor for gastric adenocarcinoma
|
atrophic gatritis
|
|
triple therapy
|
two antibiotics and proton pump inhibitor
|
|
diagnosis methods for H pylori
|
rapid urease test, histology, microbial culture on biopsy
|
|
vaccination for H pylori
|
there isnt one yet
|
|
spectrum of GI diseases linked to H pylori
|
gastric/duodenal ulceration, gastric adenocarcinoma, MALT lymphoma, NHL of stomach
|
|
H pylori inhabits the human stomach for ________
|
decades
|
|
inflammatory response to H pylori
|
low grade
|
|
describe the progression of normal gastric mucosa to gastric adenocarcinoma due to H pylori (hint: figure 22-2)
|
normal mucosa; h pylori colonization ; weeks later superficial gastritis ; years later chronic gastritis ; atrophic gastritis ; intestinal metaplasia; dysplasia ; gastric adenocarcinoma
|
|
H pylori is present in ___________% of world pop
|
50%
|
|
risk factors for H pylori infection
|
low SES, overcrowding, ethnicity, endemic infection rates in nation of origin, developing countries
|
|
reduces risk of gastric AdenoCA
|
eradication of H pylori infection
|
|
to reduce risk the H pylori need be eradicated before development of
|
premalignant lesions (intestinal metaplasia)
|
|
urease
|
allows H pylori to survive in acidic environment of stomach
|
|
rxn of urease
|
urea to ammonia and CO2 (ammonia neutralizes acid)
|
|
how does H pylori overcome gastric peristalsis
|
efficient motility (polar flagella) as well as chemotaxis and adherence to gastric epithelium
|
|
percent of H pylori that adhere to epithelium vs free floating
|
20% adhere
|
|
polar flagella allow H pylori to do what
|
move through gastric mucus layer efficiently
|
|
BabA
|
blood group antigen binding adhesin ; binds to Lewis blood group antigens present on gastric mucosal surface
|
|
SabA
|
sialic acid binding adhesin ; binds to lewis X antigens present on gastric mucosal surface
|
|
expression of BabA and SabA on H pylori is associated with
|
increased gastric cancer risk
|
|
H pylori flagella/LPS have this advantage
|
they are less immunogenic than those of other bacteria
|
|
immune defenses of H pylori
|
undergoes phase variation and expresses human lewis antigens on its LPS
|
|
VacA (vacuolating cytotoxin A ) can modulate host immune resoinse by
|
directly supressing T lymphocyte responses
|
|
inflammatory response to H pylori resulting in loss of epithelal glands
|
atrophic gastritis
|
|
atrophic gastritis is a risk factor for
|
gastric adenoCA and MALT lymphoma
|
|
virulence factors associated with peptic ulceration and carcinogenesis
|
cagA
|
|
genomic location of cagA
|
cag pathogenicity island
|
|
cagA is a ______________ toxin
|
type 4 secretion system
|
|
what does cagA do after it is introduced to host epithelial cells
|
activates host signaling pathways leading to disruption of tight and adherens junctions
|
|
cagA is presint in _______% of duodenal ulcer pt
|
90%
|
|
inflammation is higher in strains with cagA , this is displayed by the presense of this potent inflammatory cytokine
|
IL8
|
|
VacA induces this in epithelial cells, cagA presense does what to this
|
vacA induces apoptosis, cagA inhibits that apoptosis
|
|
additional effects of vacA
|
acts as a pore that allows H pylori to become permeable to urea, increases permeabiltiy to key nutrients
|
|
effect of H pylori on endocrine activity in stomach
|
downregulate D cells (somatostatin) leading to increased gastrin and increased gastric acid secretion
|
|
what contributes to ulceration specifically in duodenum
|
metaplasia to gastric epithelium which results in increased acid production
|
|
basis of progression to carcinoma due to h pylori
|
h pylori increases proliferation, decreases apoptosis, resulting in long term exposure of injured cell to inflammatory mediators
|
|
mutation that increases risk of atrophic gastritis
|
polymorphism that increases expression of IL-1 and TNF alpha
|
|
role of gastrin in H pylori infection
|
hypergastrinemia occurs early, stimulates epithelial cell proliferation and preceeds atrophic gastritis
|
|
inexpensive and sensitive stain for H pylori
|
geisma stain
|
|
steiner and warthin starry stain
|
sensitive and expensive stains for H pylori
|
|
assays for this can confirm H pylori
|
urease, catalase, oxidase
|
|
noninvasive test of choice for h pylori
|
urea breath test and stool antigen tests
|
|
serologic test for H pylori
|
IgG ELISA
|
|
how does urea breath test work
|
radiolabeled urea ingested, if metabolized by H pylori to ammonia the radioactive CO2 will be detected in breath samples
|
|
HpSA
|
H pylori stool antigen, test is both sensitive and specific
|
|
stool antigen is no longer present how long after infection clears
|
5 days
|
|
limitations of H pylori treatment, what does this mean for when we should diagnose/treat
|
rapid developing resistance, reduced efficacy and noncompliance are making treatment less effective, as such we should only test and treat those with present/past hx of PUD, MALT lymphoma, or nonulcer dyspepsia
|
|
definition of sucessful eradication of H pylori
|
negative test 4 or more weeks post therapy
|
|
antibiotics of choice for H pylori
|
clarithromycin and amoxicillin or metronidazole
|
|
why is it preferable to use amoxicillin instead of metronidazole in first line tx
|
2nd line tx involve metronidazole
|
|
quadruple therapy
|
PPI, bismuth subsalicylate, metronidazole, tetracycline 14 days
|
|
sequential therapy
|
10 days: first 5 are amoxicillin BID, then for 5 more daus use triple therapy of PPI clathriomycin and metronidazole BID
|